Lung cancer screening program for patients with COPD or emphysema
Registry of Patients Included in the DEPRECAP (Lung Cancer Screening Porgramme by Low-dose Computed Tomography for Patients With Chronic Obstructive Pulmonary Disease (COPD) or Emphysema.
This study is testing if regular lung cancer screenings can help people with COPD or emphysema catch lung cancer earlier and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1998 (estimated) |
| Ages | 55 Years to 75 Years |
| Sex | All |
| Sponsor | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Academic / other |
| Locations | 2 sites (Madrid and 1 other locations) |
| Trial ID | NCT06690385 on ClinicalTrials.gov |
What this trial studies
The DEPRECAP study is an ongoing observational program aimed at screening for lung cancer in individuals with COPD or emphysema. It recruits participants from pulmonary clinics in Madrid, Spain, and involves annual low-dose computed tomography (LDCT) and pulmonary function tests until participants reach age 75 or have 15 years of smoking abstinence. The study seeks to gather scientific evidence on the benefits of lung cancer screening in this high-risk population and aims to reduce mortality rates associated with late-stage lung cancer diagnosis. Additionally, it will create a registry of clinical, radiological, functional data, and biological samples for future research.
Who should consider this trial
Good fit: Ideal candidates are current or former smokers aged 55-75 with a history of significant smoking exposure and a diagnosis of COPD or emphysema.
Not a fit: Patients with a recent history of cancer or other serious medical conditions that pose a significant risk of death may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce lung cancer mortality rates in patients with COPD or emphysema through early detection.
How similar studies have performed: Other studies have shown success with similar lung cancer screening approaches in high-risk populations, indicating potential for positive outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current or former smokers (\>15 years of abstinence) with a cumulative smoking exposure of \> 30 pack-years * Diagnosis of COPD according to the GOLD guidelines and/or emphysema identified by LDCT and/or a carbon monoxide diffusing capacity (DLCO) lower than 80% of predicted (as per the Global Lung Function Initiative (GLI) equations) Exclusion Criteria: * Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded from the study.
Where this trial is running
Madrid and 1 other locations
- Fundación Jimenez Díaz Universitary Hospital — Madrid, Spain (Recruiting)
- Pneumology department. Fundación Jimenez Díaz University Hospital — Madrid, Spain (Recruiting)
Study contacts
- Principal investigator: Carolina Gotera, MD — Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Study coordinator: Carolina Gotera, MD
- Email: carolina.gotera@fjd.es
- Phone: +34 915504800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.